LINC02289: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

Target Name: LINC02289

NCBI ID: G102724190

LINC02289

Other Name(s): long intergenic non-protein coding RNA 2289 | Long intergenic non-protein coding RNA 2289

LINC02289: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

LINC02289 is a long non-coding RNA (lncRNA) that has been identified in various cellular and biological processes. It is expressed in various tissues and cells throughout the body and has been associated with various diseases, including cancer, neurodegenerative diseases, and developmental disorders. LINC02289 has also been identified as a potential drug target and biomarker, which may be useful for the development of new therapeutic approaches for these diseases.

Disease-Related Significance

LINC02289 has been associated with various diseases, including cancer, neurodegenerative diseases, and developmental disorders. For example, studies have shown that LINC02289 is overexpressed in various cancer types, including breast, ovarian, and colorectal cancers. Additionally, LINC02289 has been associated with neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

In addition to its association with disease, LINC02289 has also been shown to play a role in various biological processes, including cell division, apoptosis, and inflammation. For example, studies have shown that LINC02289 is involved in the regulation of cell cycle progression and has been shown to interact with various transcription factors, including DNMT1.

Potential Drug Target

The potential drug target for LINC02289 is its role in cell division and apoptosis. LINC02289 has been shown to play a role in the regulation of cell cycle progression and has been shown to interact with various transcription factors, including DNMT1. This suggests that LINC02289 may be a useful drug target for diseases that are characterized by disruptions in cell division and apoptosis, such as cancer and neurodegenerative diseases.

Biomarker

LINC02289 has also been identified as a potential biomarker for various diseases, including cancer and neurodegenerative diseases. Studies have shown that LINC02289 is expressed in various tissues and cells throughout the body and has been associated with the development and progression of various diseases. For example, studies have shown that LINC02289 is overexpressed in various cancer types, including breast, ovarian, and colorectal cancers. Additionally, LINC02289 has been associated with neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

Conclusion

In conclusion, LINC02289 is a long non-coding RNA that has been associated with various diseases, including cancer, neurodegenerative diseases, and developmental disorders. Its potential as a drug target and biomarker makes it an attractive target for the development of new therapeutic approaches for these diseases. Further research is needed to fully understand the role of LINC02289 in these diseases and to develop effective therapies.

Protein Name: Long Intergenic Non-protein Coding RNA 2289

The "LINC02289 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02289 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets